Skip to Content



Leukemia Insights - Summer 2007

  1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
  2. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419-1432.
  3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
  4. Haase D, Germing U, Schanz J, et a. New and comprehensive cytogenetic prognostication and categorization in MDS. Blood. 2006;108:abstract 248.
  5. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood.  2005;106:803-811.
  6. Jadersten M, Malcovati L, Dybedal I, et a. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood. 2006;108:abstract 521.
  7. Leitch H, Goodman T, Wong K, et a. Improved survival in patients with myelodysplastic syndromes (MDS) receiving iron chelation therapy. Blood. 2006;118:abstract 249.
  8. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.
  9. Garcia-Manero G, Yang AS, Giles F, et a. Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). Blood. 2006;108:abstract 1954.

© 2015 The University of Texas MD Anderson Cancer Center